Pharmacogenetic Tools for Malaria and Tb in the Developing World

• Nosten F , WhiteNJ: Artemisinin-based combination treatment of falciparum malaria.Am. J. Trop. Med. Hyg.77(Suppl. 6) , 181–192 (2007).
   PubMed Web of Science ®Google Scholar
• Cox HS , MorrowM, DeutschmannPW: Long term efficacy of DOTS regimens for tuberculosis: systematic review.Br. Med. J.336(7642) , 484–487 (2008).
   PubMedGoogle Scholar
• Tostmann A , BoereeMJ, AarnoutseRE, de Lange WC, van der Ven AJ, Dekhuijzen R: Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol.23(2) , 192–202 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor WR , WhiteNJ: Antimalarial drug toxicity: a review.Drug Saf.27(1) , 25–61 (2004).
   PubMed Web of Science ®Google Scholar
• White NJ : Cardiotoxicity of antimalarial drugs.Lancet Infect. Dis. (8) , 549–558 (2007).
   PubMed Web of Science ®Google Scholar
• Dye C , ScheeleS, DolinP, PathaniaV, RaviglioneMC: Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.JAMA282(7) , 677–686 (1999).
   PubMed Web of Science ®Google Scholar
• White NJ : Antimalarial drug resistance.J. Clin. Invest.113(8) , 1084–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Sachs JD , HotezPJ: Fighting tropical diseases.Science311(5767) , 1521 (2006).
   PubMed Web of Science ®Google Scholar
• Wu AC , FuhlbriggeAL: Economic evaluation of pharmacogenetic tests.Clin. Pharmacol. Ther.84(2) , 272–274 (2008).
   PubMed Web of Science ®Google Scholar
• Grossman I : Routine pharmacogenetic testing in clinical practice: dream or reality?Pharmacogenomics8(10) , 1449–1459 (2007).
   PubMed Web of Science ®Google Scholar
• Harries AD , DyeC: Tuberculosis.Ann. Trop. Med. Parasitol.100(5–6) , 415–431 (2006).
   PubMed Web of Science ®Google Scholar
• Selikoff IJ , RobitzekEH, OrnsteinGG: Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid.JAMA150 , 973–980 (1952).
   PubMed Web of Science ®Google Scholar
• Jindani A , DoréCJ, MitchisonDA: Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days.Am. J. Respir. Crit. Care Med.167(10) , 1348–1354 (2003).
   PubMed Web of Science ®Google Scholar
• Mitchison DA : Role of individual drugs in the chemotherapy of tuberculosis.Int. J. Tuberc. Lung Dis.4(9) , 796–806 (2000).
   PubMed Web of Science ®Google Scholar
• Mitchison DA : Basic mechanisms of chemotherapy.Chest76(Suppl. 6) , 771–781 (1979).
   PubMed Web of Science ®Google Scholar
• Donald PR , SirgelFA, BothaFJ et al.: The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis.Am. J. Respir. Crit. Care Med.156(3 Pt 1) , 895–900 (1997).
   PubMed Web of Science ®Google Scholar
• Donald PR , SirgelFA, VenterA et al.: The influence of human N acetyltransferase genotype on the early bactericidal activity of isoniazid.Clin. Infect. Dis.39 , 1425–1430 (2004).
   PubMed Web of Science ®Google Scholar
• Weber WW : The acetylation genes and drug response. Oxford University Press, NY, USA (1987).
   Google Scholar
• Peloquin CA , JareskoGS, YongCL, KeungAC, BulpittAE, JelliffeRW: Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.Antimicrob. Agents Chemother.41(12) , 2670–2679 (1997).
   PubMed Web of Science ®Google Scholar
• Kinzig-Schippers M , Tomalik-ScharteD, JetterA et al.: Should we use N acetyltransferase type 2 genotyping to personalize isoniazid doses?Antimicrob. Agents Chemother.49(5) , 1733–1738 (2005).
   PubMed Web of Science ®Google Scholar
• Parkin DP , VandenplasS, BothaFJ et al.: Trimodality of isoniazid elimination, phenotype and genotype in patients with tuberculosis.Am. J. Respir. Crit. Care Med.155 , 1717–1722 (1997).
   PubMed Web of Science ®Google Scholar
• Weiner MW , BurmanA, VernonD et al.: Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.Am. J. Respir. Crit. Care Med.167 , 1341–1347 (2003).
   PubMed Web of Science ®Google Scholar
• Hughes HB : On the metabolic fate of isoniazid.J. Pharmacol. Exp. Therap.109 , 444–452 (1953).
   PubMed Web of Science ®Google Scholar
• Blum M , GrantDM, McBrideW, HeimM, MeyerUA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.DNA Cell Biol.9(3) , 193–203 (1990).
   PubMed Web of Science ®Google Scholar
• Zang Y , DollMA, ZhaoS, StatesJC, HeinDW: Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2.Carcinogenesis28(8) , 1665–1671 (2007).
   PubMed Web of Science ®Google Scholar
• Leff MA , FretlandAJ, DollMA, HeinDW: Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype.J. Biol. Chem.274 , 34519–34522 (1999).
   PubMed Web of Science ®Google Scholar
• Deguchi T , MashimoM, SuzukiT: Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver.J. Biol. Chem.265(22) , 12757–12760 (1990).
   PubMed Web of Science ®Google Scholar
• Kita T , TanigawaraY, ChikazawaS et al.: N-acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.Biol. Pharm. Bull.24(5) , 544–549 (2001).
   PubMed Web of Science ®Google Scholar
• Chen B , LiJH, XuYM, WangJ, CaoXM: The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetylisoniazid in Chinese pulmonary tuberculosis patients.Clin. Chim. Acta365(1–2) , 104–108 (2006).
   PubMed Web of Science ®Google Scholar
• Hiratsuka M , KishikawaY, TakekumaY et al.: Genotyping of the N acetyltransferase 2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.Drug Metab. Pharmacokinet.17(4) , 357–362 (2002).
   PubMedGoogle Scholar
• Weber WW , HeinDW: N-acetylation pharmacogenetics.Pharmacol. Rev.37 , 25–79 (1985).
   PubMed Web of Science ®Google Scholar
• Cho HJ , KohWJ, RyuYJ et al.: Genetic polymorphisms of NAT2 and CYP2E1associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis.Tuberculosis87(6) , 551–556 (2007).
   PubMed Web of Science ®Google Scholar
• Huang YS , ChernHD, SuWJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.Hepatology35(4) , 883–889 (2002).
   PubMed Web of Science ®Google Scholar
• Possuelo LG , CastelanJA, de Brito TC et al.: Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol.64(7) , 673–681 (2008).
   PubMed Web of Science ®Google Scholar
• Ohno M , YamaguchiI, YamamotoI et al.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity.Int. J. Tuberc. Lung Dis.4(3) , 256–261 (2000).
   PubMed Web of Science ®Google Scholar
• Huang YS , ChernHD, SuWJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis.Hepatology37(4) , 924–930 (2003).
   PubMed Web of Science ®Google Scholar
• Kubota R , OhnoM, HasunumaT, IijimaH, AzumaJ: Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.Eur. J. Clin. Pharmacol.63(10) , 927–933 (2007).
   PubMed Web of Science ®Google Scholar
• Deen JL , von Seidlein L, Dondorp A: Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop. Med. Int. Health13(9) , 1111–1130 (2008).
   PubMed Web of Science ®Google Scholar
• Hatton CS , PetoTE, BunchC et al.: Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria.Lancet1(8478) , 411–414 (1986).
   PubMed Web of Science ®Google Scholar
• Neftel KA , WoodtlyW, SchmidM, FrickPG, FehrJ: Amodiaquine induced agranulocytosis and liver damage.Br. Med. J.292(6522) , 721–723 (1986).
   PubMed Web of Science ®Google Scholar
• Larrey D , CastotA, PëssayreD et al.: Amodiaquine-induced hepatitis. A report of seven cases.Ann. Intern. Med.104(6) , 801–803 (1986).
   PubMed Web of Science ®Google Scholar
• Jewell H , MaggsJL, HarrisonAC, O‘NeillPM, RuscoeJE, ParkBK: Role of hepatic metabolism in the bioactivation and detoxification of amodiaquine.Xenobiotica25 , 199–217 (1995).
   PubMed Web of Science ®Google Scholar
• Clarke JB , MaggsJL, KitteringhamNR, ParkBK: Immunogenicity of amodiaquine in the rat.Int. Arch. Allergy Appl. Immunol.91(4) , 335–342 (1990).
   PubMedGoogle Scholar
• Tingle MD , JewellH, MaggsJL, O‘NeillPM, ParkBK: The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution.Biochem. Pharmacol.50 , 1113–1119 (1995).
   PubMed Web of Science ®Google Scholar
• Olliaro P , NevillC, LeBrasJ et al.: Systematic review of amodiaquine treatment in uncomplicated malaria.Lancet348(9036) , 1196–1201 (1996).
   PubMed Web of Science ®Google Scholar
• Bloland PB , RuebushTK: Amodiaquine.Lancet348(9042) , 1659–1660 (1996).
   PubMed Web of Science ®Google Scholar
• Olliaro P , MussanoP: Amodiaquine for treating malaria.Cochrane Database Syst. Rev. (2) , CD000016 (2003).
   PubMed Web of Science ®Google Scholar
• Adjuik M , AgnameyP, BabikerA et al.: Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized, multicentre trial.Lancet359(9315) , 1365–1372 (2002).
   PubMed Web of Science ®Google Scholar
• Orrell C , TaylorWR, OlliaroP: Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.Trans. R. Soc. Trop. Med. Hyg.95(5) , 517–518 (2001).
   PubMed Web of Science ®Google Scholar
• Orrell C , LittleF, SmithP et al.: Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.Eur. J. Clin. Pharmacol.64(7) , 683–690 (2008).
   PubMed Web of Science ®Google Scholar
• Enayetallah AE , FrenchRA, ThibodeauMS, GrantDF: Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues.J. Histochem. Cytochem.52(4) , 447–454 (2004).
   PubMed Web of Science ®Google Scholar
• Klose TS , BlaisdellJA, GoldsteinJA: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.J. Biochem. Mol. Toxicol.13(6) , 289–295 (1999).
   PubMed Web of Science ®Google Scholar
• Li XQ , BjorkmanA, AnderssonTB, RidderstromM, MasimirembwaCM: Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate.J. Pharmacol. Exp. Ther.300(2) , 399–407 (2002).
   PubMed Web of Science ®Google Scholar
• Gil J , Gil Berglund E: CYP2C8 and antimalaria drug efficacy. Pharmacogenomics, 8(2) , 187–198 (2007).
   PubMed Web of Science ®Google Scholar
• Parikh S , OuedraogoJB, GoldsteinJA, RosenthalPJ, KroetzDL: Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.Clin. Pharmacol. Ther.82(2) , 197–203 (2007).
   PubMed Web of Science ®Google Scholar
• Cavaco I , Strömberg-NörklitJ, KanekoA et al.: CYP2C8 polymorphism frequencies among malaria patients in Zanzibar.Eur. J. Clin. Pharmacol.61(1) , 15–18 (2005).
   PubMed Web of Science ®Google Scholar
• Dai D , ZeldinDC, BlaisdellJA et al.: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.Pharmacogenetics11(7) , 597–607 (2001).
   PubMedGoogle Scholar
• Walsky RL , ObachRS: Validated assays for human cytochrome P450 activities.Drug Metab. Dispos.32(6) , 647–660 (2004).
   PubMed Web of Science ®Google Scholar
• Hruska MW , FryeRF, LangaeeTY: Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes.Clin. Chem.50(12) , 2392–2395 (2004).
   PubMed Web of Science ®Google Scholar
• Weise A , GrundlerS, ZaumsegelD et al.: Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping.Clin. Lab.50(3–4) , 141–148 (2004).
   PubMedGoogle Scholar
• Adjei GO , KristensenK, GokaBQ et al.: Effect of concomitant artesunate administration and CYP2C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria.Antimicrob. Agents Chemother. PMID: 18779360 (2008) (Epub ahead of print).
   Google Scholar
• Shillcutt S , MorelC, GoodmanC et al.: Cost–effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy.Bull. World Health Organ.86(2) , 101–110 (2008).
   PubMed Web of Science ®Google Scholar
• Bhattarai A , AliAS, KachurSP et al.: Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar.PLoS Med.4(11) , E309 (2007).
   PubMed Web of Science ®Google Scholar
• Cavaco I , AsimusS, Peyrard-JanvidM et al.: The Vietnamese Khin population harbours particular N acetyltransferase 2 allele frequencies.Clin. Chem.53(11) , 1977–1979 (2007).
   PubMed Web of Science ®Google Scholar
• Okello D , FloydK, AdatuF, OdekeR, GargioniG: Cost and cost–effectiveness of community-based care for tuberculosis patients in rural Uganda.Int. J. Tuberc. Lung Dis.7(9 Suppl. 1) , S72–S79 (2003).
   PubMed Web of Science ®Google Scholar
• Floyd K , SkevaJ, NyirendaT, GausiF, SalaniponiF: Cost and cost–effectiveness of increased community and primary care facility involvement in tuberculosis care in Lilongwe District, Malawi.Int. J. Tuberc. Lung Dis.7(9 Suppl. 1) , S29–S37 (2003).
   PubMed Web of Science ®Google Scholar
• Roy PD , MajumderM, RoyB: Pharmacogenomics of anti-TB drugs-related hepatotoxicity.Pharmacogenomics9(3) , 311–321 (2008).
   PubMed Web of Science ®Google Scholar
• Patin E , BarreiroLB, SabetiPC et al.: Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.Am. J. Hum. Genet.78(3) , 423–436 (2006).
   PubMed Web of Science ®Google Scholar
• Cavaco I , ReisR, GilJP, RibeiroV: CYP3A4*1B and NAT2*14 alleles in a native African population.Clin. Chem. Lab. Med.41(4) , 606–609 (2003).
   PubMed Web of Science ®Google Scholar
• Patin E , HarmantC, KiddKK et al.: Sub-Saharan African coding sequence variation and haplotype diversity at the NAT2 gene.Hum. Mutat.27(7) , 720 (2006).
   PubMed Web of Science ®Google Scholar
• Sabbagh A , LanganeyA, DarluP, GérardN, KrishnamoorthyR, PoloniES: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history.BMC Genet.9 , 21 (2008).
   PubMed Web of Science ®Google Scholar
• German P , GreenhouseB, CoatesC et al.: Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz.Clin. Infect. Dis.44(6) , 889–891 (2007).
   PubMed Web of Science ®Google Scholar
• Mallal S , PhillipsE, CarosiG et al.: PREDICT-1 Study Team. HLA-B*5701screening for hypersensitivity to abacavir.N. Engl. J. Med.358(6) , 568–579 (2008).
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M : Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.N. Engl. J. Med.358(6) , 637–639 (2008).
   PubMed Web of Science ®Google Scholar
• Cavaco I , GilJP, Gil-BerglundE, RibeiroV: CYP3A4 and MDR1alleles in a Portuguese population.Clin. Chem. Lab. Med.41(10) , 1345–1350 (2003).
   PubMed Web of Science ®Google Scholar
• Sabbagh A , LanganeyA, DarluP, GérardN, KrishnamoorthyR, PoloniES: Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history.BMC Genet.9 , 21 (2008).
   PubMed Web of Science ®Google Scholar
• Leff MA , FretlandAJ, DollMA, HeinDW: Novel human N acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype.J. Biol. Chem.274(49) , 34519–34522 (1999).
   PubMed Web of Science ®Google Scholar
• Mount DL , PatchenLC, Nguyen-DinhP, BarberAM, SchwartzIK, ChurchillFC: Sensitive analysis of blood for amodiaquine and three metabolites by high-performance liquid chromatography with electrochemical detection.J. Chromatogr.383(2) , 375–386 (1986).
   PubMed Web of Science ®Google Scholar
• Harrison AC , KitteringhamNR, ClarkeJB, ParkBK: The mechanism of bioactivation and antigen formation of amodiaquine in the rat.Biochem. Pharmacol.43(7) , 1421–1430 (1992).
   PubMed Web of Science ®Google Scholar

Websites

• World Health Organization. The WHO Global Tuberculosis Program www.who.int/gtb
   Google Scholar
• World Health Organization (2006). WHO guidelines for the treatment of malaria www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
   Google Scholar
• World Health Organization (2006). Facts on ACT (artemisinin based combinantions) www.who.int/malaria/wmr2008/malaria2008.pdf
   Google Scholar
• Sanofi Aventis: Coarsucam™ (artesunate/amodiaquine) first fixed-dose antimalarial combination to receive WHO Prequalification www.webdisclosure.com/news/45008.html
   Google Scholar
• WHO treatment policies www.who.int/malaria/treatmentpolicies.html
   Google Scholar
• Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.cypalleles.ki.se
   Google Scholar
• International HapMap Project www.hapmap.org
   Google Scholar
• Consensus arylamine N-acetyltransferase (NAT) gene nomenclature www.louisville.edu/medschool/pharmacology/NAT.html
   Google Scholar